Summary Information about the costs of recurrent breast cancer is potentially important for targeting cost containment strategies and analysing the cost-effectiveness of breast cancer control programmes. We estimated these costs by abstracting health service and consumable usage data from the medical histories of 128 patients. and valuing each of the resources used. Resource usage and costs were summarised by regarding the recurrence as a series of episodes which were categorised into five anatomical site-based groups according to the following hierarchy: visceral, central nervous system (CNS). bone. local and other. Hospital visits and investigations comprised 7800/ of total costs for all episodes combined, and there were significant differences between the site-based groups in the frequency of hospital visits and most investigations. Total costs were most accurately described by separate linear regression models for each group. with the natural logarithm of the cost of the episode as the dependent variable. and predictor variables including the duration of the episode. duration squared. duration cubed and a variable indicating whether the episode was fatal. Visceral and CNS episodes were associated with higher costs than the other groups and were more likelv to be shorter and fatal. A fatal recurrence of duration 15.7 months (the median for our sample) was predicted to cost S10.575 (Aus S 1988: or £4.877). Reduction of the substantial costs of recurrent breast cancer is likely to be a sizeable economic benefit of adjuvant systemic therapy and mammographic screening. We did not identify any major opportunities for cost containment dunrng the management of recurrences.
As health care expenditure escalates. the cost of many health services is coming under increasing scrutiny (Ginzberg. 1987) and the need to weigh the costs and benefits of cancer management. specifically, has been highlighted (Anonymous. 1988 : Markman. 1988 . A prerequisite for such cost-effectiveness analyses is data on health service costs during various phases of disease. but such information is often difficult to obtain. The costs of breast cancer recurrences are of particular interest because breast cancer is the most common malignancy in women in almost all countries for which incidence figures are available (Waterhouse et al.. 1982) . and relapses occur frequently. In Australia. for example. more than 5.000 women are diagnosed with breast cancer each year (Giles et al., 1987) . and 5 year mortality rates of 26% have been reported (Bonett et al., 1988) . The fact that women with breast cancer have a higher mortality rate for 20 years or more after diagnosis has also been documented (Langlands et al.. 1979) . The management of breast cancer recurrence is therefore a common clinical problem.
The costs of recurrent breast cancer are also relevant to studies of the cost-effectiveness of methods of controlling early breast cancer. A major advantage of adjuvant systemic therapy, for example, is delayed recurrence (Bonadonna & Valagussa. 1987) . Data on the costs of treating recurrent breast cancer are therefore required to evaluate the costeffectiveness of adjuvant systemic therapy. Similarly, such data would be required to analyse the cost-effectiveness of mammographic screening, which has been found in some studies to decrease breast cancer deaths (Tabar et al., 1985 The clinical costing system of another Melbourne hospital (Gray et al., 1987b (Gray et al., , 1988 (Gray et al. 1987b ) and the College of American Pathologists' workload recording system (Gray et al., 1988) 
Costs
The median (75th percentile) cost per episode for all episode groups combined was $4,295 ($10,124) and the median cost per recurrence was $11.349 ($18,258) . For the 89 patients who died, the median cost per recurrence was S11,948 ($18,771 Although this example suggests that the model predicted costs well, apart from presi, none of the variables indicating current or past site involvement were included. Table IV provides an explanation for the absence of these variables. It shows that the duration and the outcome of the episode were highly correlated with sites. The median duration and proportion dying in each group were both significantly different (P <0.001, Kruskal-Wallis test and x test for independence, respectively). The visceral and CNS episode groups were more likely to be shorter and fatal. We therefore undertook further analyses for the episodic data. with each episode The difficulties in measuring the costs of health services are well recognised and deficiencies in cost databases in the UK and US have been described (Weinstein. 1989; Rees. 1985 We are not aware of anv other studv which has estimated the costs of recurrent breast cancer in a similar manner. Baker et al. (1989) (Holman et al.. 1987) . If this prediction proves correct, the demand for terminal cancer care will increase, and. combined with advances in diagnostic technology. this will result in substantial increases in cancer care costs. Reviews of patterns of care. aimed at reducing unnecessary expenditures would therefore be expedient. but a major difficulty is that consensus on the optimal management of breast cancer. and other cancers. does not exist (Anonymous. 1988) .
In our study the two largest components of costs were hospital visits and investigations. Although savings might be anticipated if some inpatient care could be shifted to ambulatorx settings. a previous study comparing the costs of terminal cancer care for home hospice patients and patients managed traditionally suggested that major savings would be unlikely (Gray et al.. 1987) . at least in the terminal phases of illness. This Western Australian study found that the mean cost of care per patient during the last 90 days of life was approximately equal for 98 patients who were cared for by a home-based hospice service and a group of control patients sho received traditional institutional care.
A reduction in investigation rates, then. provides the main opportunity for cost containment. Brewin (1981) has expressed the view that patients with advanced cancer undergo too manv tests -particularly computed tomography. X-rays and isotope scans -with little chance of treatment plans or prognosis altering as a result. Are the investigation rates in our study justified. considering that the management of recurrent breast cancer (apart from isolated local recurrences) is palliative? In summary, we conducted a careful studs of the costs of breast cancer recurrences bv recording and valuing health service usage over the duration of the illness. Models describing cost as a function of duration, site involvement and the outcome of the recurrence were derived. The models were plausible and explained a large proportion of the interpatient variation in costs. Studies such as this can provide a valid basis for audit of cancer care and cost-effectiveness analy sis. 
